Publications

Selected refereed articles (Full publication list on pubmed.)

  1. Guo, W., Wang, Y., Yang, M., Wang, Z., Wang, Y., Chaurasia, S., Wu, Z., Zhang, M., Yadav, G., Rathod, S., et al., Yang D#. LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion by inhibiting IFN-γ-JAK-STAT1 signaling and antigen presentation. Science Advances. 2021 Feb 10;7(7):eabb3555. doi: 10.1126/sciadv.abb3555. Print 2021 Feb.
  2. Wu Z, Li S, Tang X, Wang Y, Guo W, Cao G, Chen K, Zhang M, Guan M, Yang D. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics. 2020;10(9):3939-3951doi: 10.7150/thno.39341. eCollection 2020. PubMed PMID: 32226530; PubMed Central PMCID: PMC7086350.
  3. Deng X, Li S, Kong F, Ruan H, Xu X, Zhang X, Wu Z, Zhang L, Xu Y, Yuan H, Peng H, Yang D, Guan M. Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer. Theranostics2020;10(1):265-280doi: 10.7150/thno.36045. eCollection 2020. PubMed PMID: 31903119; PubMed Central PMCID: PMC6929633.
  4. Yan J, Tung HC, Li S, Niu Y, Garbacz WG, Lu P, Bi Y, Li Y, He J, Xu M, Ren S, Monga SP, Schwabe RF, Yang D, Xie W. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice. Gastroenterology2019 Sep;157(3):793-806.e14doi: 10.1053/j.gastro.2019.05.066. Epub 2019 Jun 3. PubMed PMID: 31170413; PubMed Central PMCID: PMC6707837.
  5. Wang Y, Wang Z, Xu J, Li J, Li S, Zhang M, Yang D. Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun2018 Aug 9;9(1):3192doi: 10.1038/s41467-018-05495-9. PubMed PMID: 30093685; PubMed Central PMCID: PMC6085336.
  6. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell2018 Apr 9;33(4):706-720.e9doi: 10.1016/j.ccell.2018.03.006. Epub 2018 Apr 2. PubMed PMID: 29622465; PubMed Central PMCID: PMC6143179.
  7. Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B2020 Jan;10(1):105-112doi: 10.1016/j.apsb.2019.09.011. Epub 2019 Oct 19. Review. PubMed PMID: 31993309; PubMed Central PMCID: PMC6976993.
  8. Gu Y, Wang R, Han Y, Zhou W, Zhao Z, Chen T, Zhang Y, Peng F, Liang H, Qi L, Zhao W, Yang D, Guo Z. A landscape of synthetic viable interactions in cancer. Brief Bioinform2018 Jul 20;19(4):644-655doi: 10.1093/bib/bbw142. PubMed PMID: 28096076.
  9. Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol2016 Apr;141(1):57-64doi: 10.1016/j.ygyno.2016.01.004. PubMed PMID: 27016230; PubMed Central PMCID: PMC4967351.
  10. Chen K, Yang D, Li X, Sun B, Song F, Cao W, Brat DJ, Gao Z, Li H, Liang H, Zhao Y, Zheng H, Li M, Buckner J, Patterson SD, Ye X, Reinhard C, Bhathena A, Joshi D, Mischel PS, Croce CM, Wang YM, Raghavakaimal S, Li H, Lu X, Pan Y, Chang H, Ba S, Luo L, Cavenee WK, Zhang W, Hao X. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy. Proc Natl Acad Sci U S A2015 Jan 27;112(4):1107-12doi: 10.1073/pnas.1422640112. Epub 2015 Jan 12. PubMed PMID: 25583476; PubMed Central PMCID: PMC4313862.
  11. Song F, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X, Chen K. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res2014 Feb 15;20(4):878-89doi: 10.1158/1078-0432.CCR-13-1844. Epub 2013 Dec 18. PubMed PMID: 24352645.
  12. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, Shmulevich I, Sood AK, Chen K, Zhang W. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell2013 Feb 11;23(2):186-99doi: 10.1016/j.ccr.2012.12.020. PubMed PMID: 23410973; PubMed Central PMCID: PMC3603369.
  13. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK. Tumour angiogenesis regulation by the miR-200 family. Nat Commun2013;4:2427doi: 10.1038/ncomms3427. PubMed PMID: 24018975; PubMed Central PMCID: PMC3904438.
  14. Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics2012 Oct;13(13):1523-35doi: 10.2217/pgs.12.137. Review. PubMed PMID: 23057551; PubMed Central PMCID: PMC3603383.
  15. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA2011 Oct 12;306(14):1557-65doi: 10.1001/jama.2011.1456. PubMed PMID: 21990299; PubMed Central PMCID: PMC4159096.
  16. Yang D, Li Y, Xiao H, Liu Q, Zhang M, Zhu J, Ma W, Yao C, Wang J, Wang D, Guo Z, Yang B. Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories. Bioinformatics2008 Jan 15;24(2):265-71doi: 10.1093/bioinformatics/btm558. Epub 2007 Nov 15. PubMed PMID: 18006543.